HIV/HCV coinfected people who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured -- with outcomes worsening the longer it is put off -- indicating that treatment should not be deferred until advanced disease, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Treating only after progression to cirrhosis increased the risk of liver-related de...

The UK PROUD study of once-daily Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis (PrEP), and the French Ipergay study of "on-demand" PrEP taken before and after sex, both saw an 86% reduction in new HIV infections, researchers reported at the at the
2015 Conference on Retroviruses and Opportunistic Infections
(CROI) this week in Seattle.

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.